Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-02-20 @ 12:35 PM
Study NCT ID:
NCT02446093
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-08
First Post:
2015-04-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Sponsor:
Candel Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10
Start Date Type:
None
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-07
Completion Date Type:
ESTIMATED
First Submit Date:
2015-04-14
First Submit QC Date:
None
Study First Post Date:
2015-05-18
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-05
Last Update Post Date:
2024-01-08
Last Update Post Date Type:
ACTUAL